Advertisement

Melatonin Therapy of RBD

  • Dieter KunzEmail author
  • Frederik Bes
Chapter

Abstract

Rapid eye movement sleep behavior disorder (RBD) has two recommended Level B pharmacotherapies, according to the Best Practice Guide published by the American Academy of Sleep Medicine: clonazepam and melatonin. Melatonin, the focus of this chapter, manifests a gradual effect on RBD over weeks and lacks significant side effects. Amelioration of RBD symptoms with melatonin has been shown to outlast the time of treatment for weeks and sometimes months. Thus, melatonin treatment in RBD patients may be more than just a symptomatic aid. We summarize our center’s experience over the last 20 years and other published data on the treatment of RBD patients with melatonin. Compared to clonazepam therapy of RBD, outcome data with melatonin therapy of RBD have been reported in far fewer patients. We cite evidence for our hypothesis that one basic mode of melatonin’s therapeutic action on RBD symptoms involves the strengthening influence via the circadian timing system. Clearly, no circadian abnormality has been proven in RBD patients as yet. However, RBD is being considered as a prodromal of neurodegenerative synucleinopathies like Parkinson’s, which are mostly accompanied by a substantial breakdown of the circadian system. Melatonin is a chronobiotic, and REM sleep is under the strongest circadian influence compared to other sleep stages. We assume that restoration of the circadian timing system integrity by melatonin in the early phase before conversion to a full-blown synucleinopathy will lead, mainly via the MT1 receptor, to an improvement of the timely orchestration and integrity of all processes necessary for a proper functioning of REM sleep, which in turn would alleviate RBD. Confirmation of this hypothesis doubtlessly awaits a substantial amount of future research.

Keywords

REM sleep behavior disorder (RBD) Melatonin Melatonergic agonists Circadian rhythm Synucleinopathy Neurodegenerative disease 

Notes

Acknowledgments

We thank our patients for the continuing trust they put in us. Many of the diagnostics and treatments suggested were experimental. We thank Katharina Grohme for her participation in writing and editing of an earlier version of the manuscript. We also thank Prof. Daniel P. Cardinali for critically reviewing our manuscript.

References

  1. 1.
    Kunz D, Bes F. Melatonin effects in a patient with severe REM sleep behavior disorder: case report and theoretical considerations. Neuropsychobiology. 1997;36:211–4.CrossRefGoogle Scholar
  2. 2.
    Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc. 1958;80:2587.CrossRefGoogle Scholar
  3. 3.
    Stehle JH, von Gall C, Korf HW. Melatonin: a clock-output, a clock-input. J Neuroendocrinol. 2003;15:383–9.CrossRefGoogle Scholar
  4. 4.
    Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010;62:343–80.CrossRefGoogle Scholar
  5. 5.
    Lacoste B, Angeloni D, Dominguez-Lopez S, Calderoni S, Mauro A, Fraschini F, Descarries L, Gobbi G. Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain. J Pineal Res. 2015;58:397–417.CrossRefGoogle Scholar
  6. 6.
    Dubocovich ML, Hudson RL, Sumaya IC, Masana MI, Manna E. Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J Pineal Res. 2005;39:113–20.CrossRefGoogle Scholar
  7. 7.
    Von Gall C, Weaver D, Moek J, Jilg A, Stehle J, Korf H. Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. Ann N Y Acad Sci. 2005;1040:508–11.CrossRefGoogle Scholar
  8. 8.
    Waly NE, Hallworth R. Circadian pattern of melatonin MT1 and MT2 receptor localization in the rat suprachiasmatic nucleus. J Circadian Rhythms. 2015;13:1–7.CrossRefGoogle Scholar
  9. 9.
    Comai S, Ochoa-Sanchez R, Gobbi G. Sleep-wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice. Behav Brain Res. 2013;243:231–8.CrossRefGoogle Scholar
  10. 10.
    Kunz D, Mahlberg R. Melatonin: a chronobiotic that not only shifts rhythms. In: Lader M, Cardinali DP, Pandi-Perumal SR, editors. Sleep and sleep disorders: a neuropsychopharmacological approach. New York: Springer Science and Business Media; 2006. p. 100–6.CrossRefGoogle Scholar
  11. 11.
    Hardeland R, Poeggeler B. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent Nerv Syst Agents Med Chem. 2012;12:189–216.CrossRefGoogle Scholar
  12. 12.
    Carocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development. Clin Pharmacol. 2014;18:127–37.Google Scholar
  13. 13.
    Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther Adv Endocrinol Metab. 2013;4:13–24.CrossRefGoogle Scholar
  14. 14.
    Cardinali DP. Ma Vie en Noir. Fifty Years with melatonin and the stone of madness. Springer International Publishing; 2016.Google Scholar
  15. 15.
    DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40:781–4.CrossRefGoogle Scholar
  16. 16.
    Galley HF, Lowes DA, Allen L, Cameron G, Aucott LS, Webster NR. Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res. 2014;56:427–38.CrossRefGoogle Scholar
  17. 17.
    Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116–27.CrossRefGoogle Scholar
  18. 18.
    Braam W, Keijzer H, Struijker Boudier H, Didden R, Smits M, Curfs L. CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder? J Intellect Disabil Res. 2013;57:993–1000.PubMedGoogle Scholar
  19. 19.
    Laudon M, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014;15:15924–50.CrossRefGoogle Scholar
  20. 20.
    Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58:1–10.PubMedGoogle Scholar
  21. 21.
    Leger D, Quera-Salva MA, Vecchierini MF, Ogrizek P, Perry CA, Dressman MA. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Expert Opin Drug Saf. 2015;14:1673–85.CrossRefGoogle Scholar
  22. 22.
    Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord. 1999;14:507–11.CrossRefGoogle Scholar
  23. 23.
    Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19:591–6.CrossRefGoogle Scholar
  24. 24.
    Takeuchi N, Uchimura N, Hashizume Y, Mukai M, Etoh Y, Yamamoto K, et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci. 2001;55:267–9.CrossRefGoogle Scholar
  25. 25.
    Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281–4.CrossRefGoogle Scholar
  26. 26.
    McCarter SJ, Boswell CL, St Louis EK, Dueffert LG, Slocumb N, Boeve BF, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013;14:237–42.CrossRefGoogle Scholar
  27. 27.
    Lin CM, Chiu RNMSHY, Guilleminault C. Melatonin and REM behavior disorder. J Sleep Disord Ther. 2013;2:1–9.CrossRefGoogle Scholar
  28. 28.
    Bonakis A, Economou NT, Papageorgiou SG, Vagiakis E, Nanas S, Paparrigopoulos T. Agomelatine may improve REM sleep behavior disorder symptoms. J Clin Psychopharmacol. 2012;32:732–4.CrossRefGoogle Scholar
  29. 29.
    Nomura T, Kawase S, Watanabe Y, Nakashima K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med. 2013;52:2123–6.CrossRefGoogle Scholar
  30. 30.
    Esaki Y, Kitajima T, Koike S, Fujishiro H, Iwata Y, Tsuchiya A, et al. An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder. J Clin Sleep Med. 2016;12:689–93.CrossRefGoogle Scholar
  31. 31.
    Kashihara K, Nomura T, Maeda T, Tsuboi Y, Mishima T, Takigawa H, et al. Beneficial effects of Ramelteon on rapid eye movement sleep behavior disorder associated with Parkinson’s disease—results of a multicenter open trial. Intern Med. 2016;55:231–6.CrossRefGoogle Scholar
  32. 32.
    Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med. 2009;5:235–9.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Zulley J. Distribution of REM sleep in entrained 24 hour and free-running sleep-wake cycles. Sleep. 1980;2:377–89.CrossRefGoogle Scholar
  34. 34.
    Czeisler CA, Weitzman E, Moore-Ede MC, Zimmerman JC, Knauer RS. Human sleep: its duration and organization depend on its circadian phase. Science. 1980;210:1264–7.CrossRefGoogle Scholar
  35. 35.
    Bes FW, Jobert M, Mueller LC, Schulz H. The diurnal distribution of sleep propensity: experimental data about the interaction of the propensities for slow-wave sleep and REM sleep. J Sleep Res. 1996;5:90–8.CrossRefGoogle Scholar
  36. 36.
    Endo S, Kobayashi T, Yamamoto T, Fukuda H, Sasaki M, Ohta T. Persistence of the circadian rhythm of REM sleep: a variety of experimental manipulations of the sleep-wake cycle. Sleep. 1981;4:319–28.CrossRefGoogle Scholar
  37. 37.
    Czeisler CA, Zimmermann J, Ronda J, Moore-Ede MC, Weitzman E. Timing of REM sleep is coupled to the circadian rhythm of body temperature in man. Sleep. 1980;2:329–46.CrossRefGoogle Scholar
  38. 38.
    Lavie P. Ultrashort sleep-wake cycle: timing of REM sleep. Evidence for sleep-dependent and sleep-independent components of the REM cycle. Sleep. 1987;10:62–8.PubMedGoogle Scholar
  39. 39.
    Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci. 1995;15:3526–38.CrossRefGoogle Scholar
  40. 40.
    Wurts SW, Edgar DM. Circadian and homeostatic control of rapid eye movement (REM) sleep: promotion of REM tendency by the suprachiasmatic nucleus. J Neurosci. 2000;20:4300–10.CrossRefGoogle Scholar
  41. 41.
    Ocampo-Garcés A, Hernandez F, Palacios AG. REM sleep phase preference in the crepuscular Octodon degus assessed by selective REM sleep deprivation. Sleep. 2013;36:1247–56.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Kunz D. Melatonin in rapid eye movement disorder: why does it work? Sleep Med. 2013;14:705–6.CrossRefGoogle Scholar
  43. 43.
    Kunz D, Mahlberg R, Müller C, Tilmann A, Bes F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. 2004;89:128–34.CrossRefGoogle Scholar
  44. 44.
    Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016;173:2702–25.CrossRefGoogle Scholar
  45. 45.
    Videnovic A, Lazar AS, Barker RA, Overeem S. “The clocks that time us”—circadian rhythms in neurodegenerative disorders. Nat Rev Neurol. 2014;10:683–93.CrossRefGoogle Scholar
  46. 46.
    Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71:589–95.CrossRefGoogle Scholar
  47. 47.
    Videnovic A, Willis GL. Circadian system—a novel diagnostic and therapeutic target in Parkinson’s disease? Mov Disord. 2016;31:260–9.CrossRefGoogle Scholar
  48. 48.
    Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson’s disease. Med Sci Monit. 2010;16:BR61–7.PubMedGoogle Scholar
  49. 49.
    Brooks PL, Peever JH. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci. 2011;31:7111–21.CrossRefGoogle Scholar
  50. 50.
    Carocci A, Sinicropi MS, Catalano A, Lauria G, Genchi G. Melatonin in Parkinson’s disease. In: Rana QA, editor. A synopsis of Parkinson’s disease. Intech; 2014. p. 1–30.Google Scholar
  51. 51.
    Fifel K, Cooper HM. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson’s disease. Neurobiol Dis. 2014;71:359–69.CrossRefGoogle Scholar
  52. 52.
    Lee ML, Swanson BE, de la Iglesia HO. Circadian timing of REM sleep is coupled to an oscillator within the dorsomedial suprachiasmatic nucleus. Curr Biol. 2009;19:848–52.CrossRefGoogle Scholar
  53. 53.
    Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol. 2005;493:92–8.CrossRefGoogle Scholar
  54. 54.
    Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron. 2010;68:1023–42.CrossRefGoogle Scholar
  55. 55.
    Jego S, Glasgow SD, Herrera CG, Ekstrand M, Reed SJ, Boyce R, et al. Optogenetic identification of a rapid eye movement sleep modulatory circuit in the hypothalamus. Nat Neurosci. 2013;16:1637–43.CrossRefGoogle Scholar
  56. 56.
    Mahoney CE, McKinley Brewer J, Bittman EL. Central control of circadian phase in arousal-promoting neurons. PLoS One. 2013;8:e67173.CrossRefGoogle Scholar
  57. 57.
    Torterolo P, Sampogna S, Chase MH. Hypocretinergic and non-hypocretinergic projections from the hypothalamus to the REM sleep executive area of the pons. Brain Res. 2013;1491:68–77.CrossRefGoogle Scholar
  58. 58.
    Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, et al. Standards of Practice Committee; American Academy of Sleep Medicine. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6:85–95.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Kunz D. Chronobiotic protocol and Circadian Sleep Propensity Index: new tools for clinical routine and research on melatonin and sleep. Pharmacopsychiatry. 2004;37:139–46.CrossRefGoogle Scholar
  60. 60.
    Schenck CH, Montplaisir JY, Frauscher B, Hogl B, Gagnon JF, Postuma R, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 2013;14:795–806.CrossRefGoogle Scholar
  61. 61.
    Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14:744–8.CrossRefGoogle Scholar
  62. 62.
    Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;26:e89741.CrossRefGoogle Scholar
  63. 63.
    Turek FW, Dugovic C. RBD—an emerging clue to neurodegenerative disorders. Sleep. 2005;28:920–1.PubMedGoogle Scholar
  64. 64.
    Kunz D, Bes F. Twenty years after: Another case report of melatonin effects on REM Sleep Behavior Disorder, using Serial Dopamine Transporter Imaging. Neuropsychobiology, DOI 10.1159/000488893.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Clinic for Sleep- and Chronomedicine, St. Hedwig-Krankenhaus BerlinBerlinGermany

Personalised recommendations